StockData
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30
$9.20+0.07 (+0.77%)

Close on Nov 17, 2026Market cap $821.53MP/E –Yield –

Earnings

Syndax Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$83.30M
+81.5% on a year earlier
EPS, Q3 FY2026
-$0.55
-$0.70 a year earlier
Latest guidance
Reaffirmed
Nov 2, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Syndax Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 2, 2026after the close$83.30M+81.5%-$0.55Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026during market hours$72.80M+91.6%-$0.55Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026during market hours$64.90M+223.8%-$0.48Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026during market hours$68.70M+792.2%-$0.78Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025during market hours$45.90M+267.2%-$0.70Release
Q2 FY2025ended Jun 30, 2025Aug 4, 2025during market hours$38.00M+985.7%-$0.83Release
Q1 FY2025ended Mar 31, 2025May 5, 2025during market hours$20.04M–-$0.98Release
Q4 FY2024ended Dec 31, 2024Mar 3, 2025before the open$7.70M–-$1.10Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024during market hours$12.50M–-$0.98Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024during market hours$3.50M–-$0.80Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open––-$0.85Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Syndax Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total research and development plus selling, general and administrative expensesnon-GAAPFY2026$400.00M$400.00MReaffirmedNov 2, 2026
total research and development plus selling, general and administrative expensesnon-GAAPFY2026$400.00M$400.00MReaffirmedAug 4, 2026

Guidance history

Every forecast Syndax Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 2, 2026total research and development plus selling, general and administrative expensesFY2026$400.00MReaffirmed
Aug 4, 2026total research and development plus selling, general and administrative expensesFY2026$400.00MReaffirmed
Apr 30, 2026total research and development plus selling, general and administrative expensesFY2026$400.00MReaffirmed
Feb 26, 2026total research and development plus selling, general and administrative expensesFY2026$400.00MNew
Jan 12, 2026total research and development plus selling, general and administrative expensesFY2026$400.00MNew
Nov 3, 2025total research and development plus selling, general and administrative expensesFY2025$380.00M – $385.00MNew
Aug 4, 2025total research and development plus selling, general and administrative expensesQ3 FY2025$95.00M – $100.00MNew
Aug 4, 2025total research and development plus selling, general and administrative expensesFY2025$370.00M – $390.00MNew
May 5, 2025research and development expensesQ2 FY2025$70.00M – $75.00MNew
May 5, 2025total research and development plus selling, general and administrative expensesQ2 FY2025$110.00M – $115.00MRaised
May 5, 2025research and development expensesFY2025$260.00M – $280.00MLowered
May 5, 2025total research and development plus selling, general and administrative expensesFY2025$415.00M – $435.00MRaised
Mar 3, 2025research and development expensesQ1 FY2025$65.00M – $70.00MNew
Mar 3, 2025total research and development plus selling, general and administrative expensesQ1 FY2025$105.00M – $110.00MRaised
Mar 3, 2025research and development expensesFY2025$260.00M – $280.00MNew
Mar 3, 2025total research and development plus selling, general and administrative expensesFY2025$415.00M – $435.00MRaised
Nov 5, 2024research and development expensesFY2024$245.00M – $250.00MRaised
Nov 5, 2024total operating expensesFY2024$365.00M – $370.00MRaised
Nov 5, 2024non-cash stock compensation expenseFY2024$41.00MLowered
Aug 1, 2024research and development expensesQ3 FY2024$70.00M – $75.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Syndax Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. News
  6. News
  7. News
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. News

See a number that looks wrong?